Reproductive Technology Council

Preimplantation Genetic Diagnosis Committee

Terms of reference

The committee's terms of reference are to:

- advise the Reproductive Technology Council (Council) on a suitable framework for the approval of PGD under the Human Reproductive Technology Act 1991 (Act), both generally and for specific cases.
- advise the Council on factors that it should consider when deciding whether to approve PGD.
- advise Council on standards for facilities, staffing and technical procedures;
- approve PGD applications for Beta-thalassemia; Cystic Fibrosis; D-Bifunctional Protein Deficiency; Duchenne Muscular Dystrophy; Fragile X; Huntington's Disease; Long QT Syndrome; Myotonic Dystrophy Type 1; Myotonic Dystrophy Type 2; Retinitis Pigmentosa; Spinal Muscular Atrophy and translocations.
- advise as to how the ongoing process of approval of PGD should be managed effectively by the Council;
- advise the Council on other relevant matters as requested by the Council.

The Committee may consult with relevant experts in the preparation of this advice for the Council.